A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Autologous cultured kidney tissue cells (Primary)
- Indications Kidney disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors RegenMed
- 07 Aug 2017 Status changed from recruiting to completed.
- 14 Jul 2016 Status changed from not yet recruiting to recruiting.
- 05 Apr 2016 Planned initiation date changed from 1 Aug 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.